drugset / Trial / NCT02164565

The Use of Tranexamic Acid (TXA) Intravenously, to Reduce Blood Loss in Proximal Femur Surgery

NCT02164565 ↗

Phase 4 Withdrawn HaEmek Medical Center, Israel
RandomizedParallel-groupOpen-labelPrevention

Summary

The use of Tranexamic Acid (TXA) intravenously, to Reduce Blood Loss in proximal femur surgery.

Timeline

Start
2014-06
Primary completion
2015-01
Completion
2015-03

Outcome

Outcome not reported

Stopped (Enrollment): “Enrollment difficulties”

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule — Intravenous

Indications

No indication recorded.